Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245302 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31069783 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21351775 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30106823 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14148163 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL245303 | 1.00 | NPC1 (0.66) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL12786269 | 0.98 | NPC1 (0.64) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL7183038 | 0.97 | NPC1 (0.62) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL7171153 | 0.97 | NPC1 (0.62) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL7182624 | 0.97 | NPC1 (0.62) | NPC1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274294-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | Versitech Limited (CN) | 2011-01-19 | — | — | EP | claimed |
| US-20090247503-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | VERSITECH LIMITED (CN) | 2009-10-01 | — | — | US | claimed |
| WO-2009117902-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | VERSITECH LIMITED (CN) | 2009-10-01 | — | — | WO | claimed |
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| CN-120865258-A | Coumarin-based chiral binary Dy3+Complex enantiomer, preparation method and application thereof | 西京学院 | 2025-10-31 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| CN-112898368-B | Preparation method of obeticholic acid intermediate | 中国科学院成都有机化学有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-111039916-B | Tricyclic spiro compounds | 小野药品工业株式会社 | 2023-04-28 | — | — | CN | disclosed |
| CN-114269982-A | Fabric coating composition | 惠普发展公司，有限责任合伙企业 | 2022-04-01 | — | — | CN | disclosed |
| US-20090247503-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | VERSITECH LIMITED (CN) | 2009-10-01 | — | — | US | disclosed |
| EP-2095875-A1 | Homogeneous asymmetric hydrogenation catalyst | Takasago International Corporation (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| EP-1911516-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20080004242-A1 | Process for preparation of HIV protease inhibitors | GILEAD SCIENCES, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004242-A1 | Process for preparation of HIV protease inhibitors | GILEAD SCIENCES, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007126812-A2 | PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | HDHD5, HHAT, HACL2 | NPC1 2029/4885MAPT 3419/4885RAB9A 2049/4885 |
| US-20090247503-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | FPGS, DHFR, G6PD | NPC1 1716/4885MAPT 2433/4885RAB9A 2027/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | NPC1 577/4885MAPT 4700/4885RAB9A 2518/4885 |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | NPC1 509/4885MAPT 1912/4885RAB9A 3494/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | NPC1 2631/4885MAPT 4766/4885RAB9A 2370/4885 |
| US-20080004242-A1 | Process for preparation of HIV protease inhibitors | PRSS1, PREP, SERPINB1 | NPC1 1225/4885MAPT 2148/4885RAB9A 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.